Streetbeat News

Earnings

CRWD

FTNT

PANW

S

ZS

Cybersecurity stocks SentinelOne, Palo Alto Networks, Fortinet, and Zscaler saw gains in after-hours trading, driven by CrowdStrike's better-than-expected earnings report and positive guidance. CrowdStrike's Q4 revenue rose 33% year-over-year, beating estimates, with earnings per share also surpassing expectations. This performance has positively influenced the sector, reflecting investor optimism.

Portfolio Pulse from Adam Eckert

March 05, 2024 | 10:02 pm

ISPO

Inspirato (NASDAQ:ISPO) reported Q4 adjusted EPS of $(3.20), surpassing the $(3.66) estimate, but its sales of $70.71M fell short of the $73.50M estimate. This represents a 23.08% decrease in EPS and an 18.37% decrease in sales from the same period last year.

Portfolio Pulse from totan@benzinga.com

March 05, 2024 | 10:02 pm

DADA

Dada Nexus announced that its net revenues and operations and support costs were overstated in past financial statements, affecting four quarters from Q4 2022 to Q3 2023. The overstatements ranged from RMB40 million to RMB245 million for revenues and RMB42 million to RMB250 million for costs.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:57 pm

PRAX

Praxis Precision Medicine (NASDAQ:PRAX) reported Q4 earnings, beating estimates with an EPS of $-2.97 against the expected $-3.13. Revenue increased by $515 thousand year-over-year. Despite beating last quarter's EPS estimates, the share price dropped by 5.0% the following day.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 9:55 pm

APEI

American Public Education anticipates its full-year 2024 consolidated revenue to be between $610 million and $620 million, closely aligning with the estimated $613.725 million.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:53 pm

ELEV

Elevation Oncology, Inc. (NASDAQ:ELEV) announced its plans to present preclinical proof-of-concept data for its HER3-targeting antibody-drug conjugate (ADC) program at the AACR Annual Meeting 2024. The data supports the ongoing development of the ADC program targeting HER3-expressing cancers, with the company on track to nominate a development candidate in 2024. The presentation aims to highlight the therapeutic potential of the HER3-ADC for treating a range of solid tumors associated with poor clinical outcomes.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:52 pm

APEI

American Public Education anticipates Q1 consolidated revenue between $151M-$153M, surpassing the estimated $150.6M. However, it expects a loss per share of $(0.25)-$(0.17), contrary to the estimated earnings of $0.04 per share.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:51 pm

LXU

LSB Industries (NYSE:LXU) reported Q4 earnings with an EPS of $-0.07, missing estimates by -275.0% and a significant revenue drop from the previous year. Past quarters show mixed performance.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 9:50 pm

BNGO

Bionano Genomics (BNGO) projects Q1 revenue of $8.25M-$8.75M, below the $9.69M estimate, and FY24 revenue of $37M-$41M, under the $47.17M estimate. The company is restructuring debt and phasing out non-core products, expecting to install 80-100 new OGM systems in 2024.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:50 pm

LXU

LSB Industries (NYSE:LXU) reported a Q4 2023 GAAP EPS of $(0.07), missing the $0.05 estimate, while sales of $132.61M exceeded the $127.21M estimate. This represents a 43.24% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:46 pm